Musculoskeletal/Rheumatology

Latest News

Celltrion USA Seeks Approval for Actemra Biosimilar
Celltrion USA Seeks Approval for Actemra Biosimilar

January 29th 2024

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

FDA Approves First Biosimilar of Arthritis Med Actemra
FDA Approves First Biosimilar of Arthritis Med Actemra

October 2nd 2023

Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA

March 22nd 2023

FDA Approves Kevzara for Inflammatory Rheumatic Disease
FDA Approves Kevzara for Inflammatory Rheumatic Disease

March 1st 2023

 Will the Biosimilar Amjevita Lower Costs?
Will the Biosimilar Amjevita Lower Costs?

February 2nd 2023

More News

© 2024 MJH Life Sciences

All rights reserved.